New interview today17 Aug 2017 10:01
OptiBiotix Health PLC Q&A with CEO Stephen O’Hara (LON:OPTI)
Posted by: Amilia Stone 17th August 2017
OptiBiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara caught up with ************* for an exclusive interview to discuss the recent share price movement, their deal pipeline, the 39 potential RNS’s that could be announced in the following months & what this all means for investors
Q1: Just recently, there’s been a fall in OptiBiotix Health’s share price, how would you explain the share price performance?
A1: There has been some volatility in the share price, the first thing I wanted to do was to reassure investors that there’s nothing wrong. If you look back at where we are now to where we were say 12 months or so ago, the share price was higher 12 months or so ago but undoubtedly, we’re in a stronger position today than we were when the share price was trading at 80p. Even more importantly, if we look towards the future, there are a lot more opportunities we are progressing which are at a later stage, we touched on in previous RNS’s, and are entering the commercialisation phase. We do recognise there is uncertainty in small caps in general, and that’s across the board, and we do have a large retail investor base so we will get peaks and troughs, some shareholders just take profit and there’s also some uncertainty in the external environment which means that some retail investors start to take a shorter view.
I would say that if you look at where we are with the company, we’ve just entered a commercialisation and I believe this next stage of growth, there’s a potential for share growth which will come when we gain commercial traction with our products. Based on the high level of interest and lots of ongoing discussions, this look extremely promising and investors who attended my investor share results presentation earlier on in the year will recognise we have a structured plan and that’s the reason we appointed a new Commercial Director, Per Rehné and a new Sales Director in January 2017. They joined us at the end of March and as planned, we launched products in May and as I reported in previous RNS’s, there’s been a lot of interest, extensive interest, from our launch of Vitafoods in the middle of May, we’ve been working hard to close out deals from those discussions.
We have closed out 2 deals, one with HLH and one with Pharmabiota, both these are privately-owned pharmaceutical companies so they are far quicker in decision making. As people are also aware, HLH they had an initial order of 100,000 and last week they ordered another 200,000 units so you can see that it’s not just signing deals, HLH for example signed a deal, put the products on the market and now re-ordered twice the number of units they ordered initially. We have a number of agreements in our pipeline, 4 private companies like
Sign In
Follow the stocks
